Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Orbivate is a topical combination cream developed by Allgems Healthcare, primarily indicated for the treatment of superficial fungal infections complicated by inflammation or secondary bacterial infection. It typically contains a corticosteroid (clobetasol propionate) to reduce inflammation and itching, an antifungal agent (miconazole nitrate) to treat fungal pathogens such as *Candida* and dermatophytes, and an antibiotic (neomycin sulfate) to address bacterial involvement. This multi-action formulation is used for conditions like tinea infections (athlete's foot, jock itch, ringworm) and cutaneous candidiasis where symptomatic relief from inflammation is required alongside antimicrobial treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clobetasol propionate + miconazole nitrate + neomycin sulfate.